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The current developments of the new biological drugs targeting interleukin 5 (IL-5) and IL-5 receptor allowed to expand the
treatment options for severe hypereosinophilic asthma. Clinicians will then be able to choose between antibodies targeting either
circulating IL-5 or its receptor expressed on eosinophils and basophils. The available clinical trials consistently reported favorable
results about the reduction of exacerbations rate, improvement in quality of life, and sparing of the systemic steroid use, with a
favorable safety profile. Two of these new drugs are administered subcutaneously, mepolizumab every 4 weeks and benralizumab
every 8 weeks, whereas reslizumab is given intravenously monthly on a weigh-based dose. In the future, the research actions will be
involved in the identification of a single biomarker or multiple biomarkers for the optimal choice of biological agents to be properly
prescribed.
1. Introduction
The recent change in the definition of asthma, from a unique
disease characterized by a reversible airway obstruction to
a heterogeneous disease (encompassing numerous pheno-
types), prompted the research to look for more detailed
pathogenic aspects, as endotypic targets, especially in uncon-
trolled or severe patients. In this regard, two main different
phenotypes/endotypes of asthma could be distinguished,
based on their inflammatory characteristics, that are, T helper
lymphocyte type 2 (TH2)-high and TH2-low, depending
on the predominance of TH2 cytokines [1]. The more and
more detailed knowledge of the pathogenic mechanisms
led to the discovery of “targeted” treatments to be used in
subsets of non-controlled asthmatic patients. For historical
and cultural reasons the best known pathogenic mechanism
is mediated by eosinophils and IL-5. In fact, within the
TH2-high asthma, allergic asthma (early onset, eosinophilic
inflammation, and IgE mediated sensitization) remains a
paradigm. Two main approaches were evaluated to block
the action of IL-5 on eosinophil activation, survival, and
migration. The first one is to block the circulating cytokine,
and the second is to interfere with the IL-5 receptor alpha on
eosinophils. Although the earliest experimental data on the
effects of anti IL-5 in asthmatic patients were disappointing,
with the only evidence that anti-IL-5 reduced eosinophils in
peripheral blood, airways, and bonemarrow, but no effects on
airway hyperreactivity and bronchial allergen [2–5], a more
accurate analysis of the data related to the first studies has
allowed to highlight a better response to these drugs by those
who had high levels of serum eosinophils. The use of these
drugs has therefore been restricted to asthmatic patients with
these biochemical characteristics.
The subsequent available clinical trials have shown a good
efficacy in the above mentioned selected patients, with a
favorable safety profile, for all of the three drugs [6].
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2. IL-5 and Its Receptor Alpha
IL-5 is a 13-amino acid protein forming a 52-kDa homodimer,
which has long been evaluated as a valuable therapeutic
target [22], since it represents the main stimulus for growth,
differentiation, survival, and activation of the cells [23]. IL-
5, IL-3, and granulocyte-monocyte colony-stimulating factor
(GM-CSF) all belong to the 𝛽 common chain family and are
able to bind a receptor involving the interleukin-5Ra and the
common 𝛽 subunit 𝛽c [24–26]. While IL-5 is more specif-
ically involved in maturation and activation of eosinophils,
IL-3 and GM-CSF have a more broad action, as survival
factors for these cells [27]. Recently, IL-33 was found to play
a non-negligible role in eosinophils homeostasis, through the
activation of innate lymphoid cells type 2 (ILC2) [28].
3. IL-5 Antagonists
The awareness that IL-5 is involved in development, matura-
tion, and action of eosinophils prompted the research to eval-
uate this cytokine as a possible therapeutic target in severe
uncontrolled hypereosinophilic asthma. Two different mech-
anisms of action were identified, the former acting directly
on IL-5 and the latter directly on IL-5 receptor alpha (IL-
5Ra). Two different drugs are currently available to block IL-
5: mepolizumab (recently commercialized with brand name
Nucala; GSK) [2, 23] and reslizumab (proposed trade name
Cinqair; Teva). Another biological drug blocking the IL-5
receptor alpha was approved by Food and Drug Adminis-
tration (FDA) (Benralizumab, Fasenra) [29].The antagonism
to circulating IL-5 is intended to decrease the proliferation,
maturation, and survival of eosinophils, whereas the ILR-a
antagonism adds an antibody-dependent cell-mediated cyto-
toxicity (ADCC). Through this activity, essentially mediated
byNK cells, Benralizumab can induce a peripheral and tissue
destruction of both eosinophils and basophils [8]. The main
end point, in clinical trials, regarding anti IL-5 or anti IL-5R
drugs, ever was the reduction of exacerbations, the use of oral
corticosteroids (OCS), and the effects on quality of life (QoL).
4. General Therapeutic Aspects
First clinical trials about these drugs evaluated the intra-
venous route of administration with the above mentioned
results. After these trials a second route has been evaluated
for all of these drugs, the subcutaneous. For mepolizumab
and benralizumab, it was shown that both routes were equally
effective, with a better safety profile and a more convenient
use of the subcutaneous route.The same thing did not happen
for reslizumab; indeed recently two phase III studies (eval-
uating subcutaneous reslizumab, 110 mg) did not meet the
primary endpoint: the reduction of exacerbations in patients
with severe uncontrolled hypereosinophilic asthma (blood
eosinophils >300/mcL) in the first one (NCT02452190)
and the reduction of daily systemic steroids in the second
(NCT02501629) [30]. Therefore, so far, the optimal admin-
istration route for reslizumab remains the intravenous one
that, on the other hand, allows to adjust the dose according
body weight. Benralizumab is administered subcutaneously,
like mepolizumab, at an 8-week time interval. The possibility
to choose between two different routes (intravenous or
subcutaneous) and a different times of administration (4
or 8 weeks) would allow the clinicians to more properly
personalize the therapy according to the characteristics of the
drugs and the patients’ needs.
5. Exacerbations
Thereduction in exacerbation rate and in the dose of systemic
corticosteroids is usually the main endpoints in clinical
trials, according to the definition of severe asthma [31].
Omalizumab (anti-IgE [32]) remained for 10 years the only
biological treatment available for severe allergic asthma. The
first regulatory trial with mepolizumab involved 61 subjects
with a history of refractory hypereosinophilic asthma and
frequent exacerbations. Patients received a monthly dose of
750 mg mepolizumab for one year. There was a reduction of
the exacerbation rate in the active arm compared with the
placebo group (2.0 vs. 3.4 mean exacerbations per subject;
relative risk, 0.57; 95% confidence interval [CI], 0.32 to 0.92; P
= 0.02) [33]. In another trial, the efficacy of mepolizumab in
reducing exacerbations was tested in 20 adult patients with
severe asthma. All patients received 750 mg mepolizumab
or placebo for five months. At the end of the study, 12
exacerbations were recorded in the placebo group and two
in the mepolizumab group (p=0.008) with a mean duration
of exacerbation of 20 weeks in the active group and 12
weeks in the placebo one (P=0.003) [11]. The first trial with
exacerbation rate formally defined as primary endpoint was
DREAM. Six hundred and twenty-one patients with severe
asthma and signs of eosinophilic inflammation were enrolled
in this multicentric, double-blind, placebo-controlled trial.
Three different intravenous dosages of mepolizumab (75 mg,
250 mg, and 750 mg) and placebo were administered. The
exacerbations rate was significantly reduced in the active
groups as compared to placebo (48% reduction; <0⋅0001) [7].
There was no difference in the efficacy and safety among
the different doses in order to reduce exacerbations. SIRIUS
study, where primary endpoint was the reduction of oral
corticosteroids (OCS), evaluated also, as further endpoint,
the exacerbations showing a significant reduction (32% less)
in patients given mepolizumab compared with placebo [9].
The effects of mepolizumab, 75 mg intravenously or 100
mg subcutaneously, were assessed in the MENSA study. In
this study, in the intravenous group the exacerbation rate
was reduced by 32%, while in the subcutaneous group the
decrease was 53% versus placebo [10].
For Reslizumab, the reduction of exacerbations was
assessed in two duplicate, multicenter, double-blind, parallel-
group, randomized, placebo-controlled (DBRPC) phase 3
trials. The drug (or placebo) was given at 3.0 mg/kg intra-
venously every 4 weeks for 1 year. The trial reported a
significant reduction in asthma exacerbations in the active
group (study 1: RISK ratio [RR] 0.50 [95% CI 0.37–0.67];
study 2: 0.41[0.28–0.59]; both p<0.0001). In addition, the time
to first exacerbation was considerably longer in the active
than in the placebo group [13].
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Similarly tomepolizumab and reslizumab, several studies
with Benralizumab evaluated the exacerbation rate reduction
as primary endpoint. The results of a phase II DBRPC
showed a reduction of exacerbations. A significant reduction
of exacerbations rate (49%) and exacerbations requiring
hospitalization (60%; 1.62 vs 0.65; P=.02), was also reported
in another trial (3.59 vs 1.82; P=.01[18]).The SIROCCO study
was a double-blind, parallel-group, placebo-controlled phase
3 clinical trial, where patients were assigned to 400 every four
weeks and 398 every eight weeks Benralizumab 30 mg or
placebo subcutaneously. The active drug reduced the asthma
exacerbation rate, during the year of observation both in
the 4-week (RISK ratio 0.55, 95% CI 0.42–0.71; p<0.0001)
and in the 8-week group (0.49, 0.37–0.64; p<0.0001) [19].
Exacerbation reduction has been evaluated also in CALIMA
study, with the same inclusion criteria and dosing regimens
of SIROCCO, showing similar results with a significantly
lower annual exacerbation rate both in the group treated
with 30 mg every 4 weeks (0.60 [95% CI 0.48–0.74], rate
ratio 0.64 [95% CI 0.49–0.85], p=0.0018, n=241), and in the
one treated every 8 weeks, compared with placebo [20].
The latest published clinical trial on Benralizumab in severe
hypereosinophilic patients (ZONDA) reported a significant
reduction in exacerbation rate in both groups (30mg/4 weeks
or 30 mg/8 weeks), with a decrease of 55% in patients treated
every 4 weeks, and 70% in those who assume therapy every 8
weeks, versus the one treated with placebo [21].
6. The OCS Sparing Effect
Aspecial attentionwas recently devoted to steroid-dependent
patients; this was due to the well-known burden of steroid
related side effects (diabetes, hypertension, obesity, cataract,
etc.) [34]. In one study, all enrolled patients received a mean
daily dose of 10 mg of prednisone both in placebo and in
mepolizumab group. After the treatment period, the active
group had a mean reduction of their dose of 83.8 ± 33.4%,
as compared to 47.7 ± 40.5% in the control group (P=0.04)
[11]. In the SIRIUS study, in a cohort of 135 patients with
severe eosinophilic asthma those receiving mepolizumab
could reduce the dose of oral steroids 2.65 times versus those
receiving placebo (95% CI, 1.25 to 4.56; P=0.008) [9]. A trial
where reslizumab’s OCS sparing effect has been indicated
as primary endpoint is actually ongoing (NCT02501629).
Preliminary results of this trial have been recently published
in an official note, showing the failure of the drug in order to
reduce daily OCS dose [30]. The effect of Benralizumab, on
the reduction in the OCS dose, has been recently published.
The study design involved 28 weeks of Benralizumab (30
mg subcutaneously, either every 4 weeks or every 8 weeks
[with the first three doses administered every 4 weeks])
versus placebo. For both active groups, the median OCS
reduction at week 28 was 75% in active patients compared
with 25% in the placebo group.Thepercentage of patients that
could completely withdraw their OCS daily dose (secondary
endpoint) was 56% in the every 4 weeks and 52% in the every
8 weeks administration, as compared with 19% in the placebo
group [21].
7. Quality of Life (QoL)
In addition to exacerbations, lung function, and safety, the
effects on QoL are also relevant when a new drug is evalu-
ated. Within the above mentioned trials with mepolizumab,
Haldar et al. evaluated the effect of the medication on
QoL, measured by the Asthma Quality of Life Questionnaire
(AQLQ). After treatment, AQLQ improved from 0.55 in the
active group to 0.19 [33]. On the other hand, the DREAM
study failed to demonstrate a statistically significant effect on
FEV
1
and AQLQ [7]. MUSCA is the most recent large trial
assessing health-related quality of life (HRQOL) in severe
asthmatic patients as primary endpoint. It is a randomized,
double blind, placebo-controlled, parallel group, multicenter,
phase 3b trial, with 274 mepolizumab patients and 277
placebo patients enrolled. Inclusion criteria were a history of
at least two exacerbations in the previous year treated with
corticosteroids. The St George’s Respiratory Questionnaire
(SGRQ) was used to assess the changes in HRQOL. At week
24 a significant improvement in symptoms in the active group
was documented as compared with placebo [12]. One of the
first trials with reslizumab evaluated the effect of 0.03 mg/kg,
0.1 mg/kg, 0.3 mg/kg, or 1.0 mg/kg or placebo, in severe
asthmatic patients with persistent symptoms, needing OCS
and high-dose of inhaled steroids. With the 1 mg/kg dose a
decrease of peripheral eosinophils was seen, but no improve-
ment in symptoms [35]. A more recent study demonstrated
a significant reduction in ACQ-7 in patients treated with
reslizumab vs placebo (71% vs. 57%; p=0.01) [15]. In a similar
trial, where reslizumab was given at 0.3 mg/kg and 3 mg/kg,
an improvement inQoL, measured with ACQ,ACQ-5, ACQ-
6, and AQLQ, was demonstrated with the highest dose [16].
Concerning Benralizumab, an improvement in QoL (ACQ-
6 and AQLQ) was seen, especially in subjects with baseline
blood eosinophils≥300 cells per 𝜇L [19, 20]. An improvement
in QoL was confirmed also in the ZONDA study, where
active armACQ-6 scores decreased by 0.55 points vs. placebo
(p=0.001) [21] (Table 1).
8. Safety
The general safety of anti-IL biologicals, as assessed in
controlled trials, has been described and reviewed elsewhere
[36, 37]. Nonetheless, other special safety aspects have been
proposed as a matter of discussion.
For instance, the defensive role of eosinophils, especially
against helminthic infections, is well known, and for
this reason the effects of the drug-induced depletion of
eosinophils were debated. Indeed, several studies in guinea
pigs treated with eosinophils antiserum failed to demonstrate
an increased risk of helminth infestation [38]. Also, the long
term (more than 6 months) treatments in mice and primates
with antibodies abating eosinophils did not demonstrate
any observable adverse effects [39, 40]. The most common
non-serious AE in clinical trials with mepolizumab were
injection site reaction, headache, nasopharyngitis, and upper
respiratory tract infection, not different from placebo groups
[7, 9–12, 33]. In the largest clinical trials, some serious
adverse events (SAE) were described, mainly worsening
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of asthma [5, 9]. Three fatal events, all in the intravenous
mepolizumab groups, were reported, but none of these cases
were considered as drug-related [7]. No fatal event was
reported with the subcutaneous route. With reslizumab, four
cases of anaphylactic reaction were described in two different
trials [13, 15]. Also for reslizumab the main SAEs were
worsening of asthma, followed by pneumonia [10, 13, 14, 16].
One patient in the placebo group died due to multiple-drug
overdose [13]. Worsening of asthma appeared as the most
frequently described SAE also in the benralizumab studies
[20, 21]. In those trials, some fatal events (due to pneumonia,
acute cardiac failure, cerebral hemorrhage, asthma, opioid
overdose, suicide, road traffic accident, acute myocardial
infarction, colon neoplasm, and unknown causes) were in
the active group patients. Pulmonary embolism, myocardial
infarction, and unknown causes were in patients treated with
placebo [17, 19–21].
9. Anti-IL-5 Treatments: Practical Aspects
and Problems
All the available (or soon available) IL-5 antagonists
(mepolizumab, reslizumab, and benralizumab) show a favor-
able cost-to-benefit profile, in addition to clinical efficacy
and biological effects. When all drugs will be marketed,
we could choose between different kinds of administration
(intravenous or subcutaneous) and administration frequency
(4 or 8 weeks). For administration route, it has been already
said that reslizumab, at least at the moment, remains with the
only intravenous way; regarding the frequency of adminis-
tration it is interesting that benralizumab could be dispensed
every 8 weeks. In published clinical trials and documents
no pathophysiological motivation was provided to explain
the possibility to doubling administration time; however it
is evident that, with the same efficacy results shown in the
CALIMA and in the SIROCCO study [19, 20] at 4-week
and 8-week administration, the pathway every 8 weeks is
economically and operationally more sustainable for this
drug.
Regardless of the route and frequency of administration,
in the main clinical trials all the above mentioned IL-5
antagonists have proven to be more effective in the severe
form of asthma with high levels of blood eosinophils (300
cells/mm3 for Benralizumab and mepolizumab and 400
cells/mm3 for reslizumab). The fact that it has been proven
that all three drugs are more effective in the same types of
subjects (severe asthmatics with serum hypereosinophilia),
once on the market, could be a problem. Indeed if we have
three drugs with similar patient targets, and a very similar
efficacy between the different molecules, it will be difficult
to choose [41]. Moreover, regarding efficacy, it has been
shown that all anti-IL-5 drugs not only need high blood
eosinophils levels, but also highlight the fact that the number
of eosinophils present in patients’ serum correlates with
the effect of the drug administered. Indeed a secondary
analysis of MENSA and DREAM studies demonstrates that
the reduction in exacerbations rate is positively associated
with increasing blood eosinophil count at baseline [42].
Nevertheless, the clinical aspects (symptoms, pulmonary
function, exacerbations, and exhaled nitric oxide) still per-
ceived the only (and insufficient) predictive biomarkers to
guide the prescription of such expensive drugs. The coexis-
tence of chronic rhino sinusitis with nasal polyposis could
be a criterion for the choice of one drug or other biological
drugs. Also, the route of administration (intravenous or
subcutaneous) and the possibility of adjusting the dosage
would be possible suggestions for clinicians. In addition to
IL-5 antagonists, other biological drugs such as anti IL-4 and
IL-13 [43] were proposed, although the recent preliminary
results on Tralokinumab (anti IL-13) displayed unfavorable
results (STRATOS 2 (exacerbations) and TROPOS reduction
in OCS use) in severe asthma [44]. The possible answer
is biomarkers, some biological or clinical samples, able to
drive clinician to the choice [45]. Notwithstanding some
studies proposed several biomarkers, such as serum total
IgE levels (IgEs) [46], FeNO, blood, and sputum eosinophil
count [47, 48]; there is not a certain role of these samples
as predictive indicator of response for one or the other
drug. Other biological samples have been evaluated, like
periostin, both in bronchoscopy biopsies [49] and in less
invasive way [50], and are still under evaluation. Given that
clinical trials have shown promising efficacy for all three
drugs described, as already stated, once all these drugs are
marketed the challenge could be which one to choose to
provide an increasingly personalized medicine and choose
the one that preventively could be the best. At the moment,
due to the fact that no certain biomarker has been discovered,
to choose the better drug for our patients, we could use a
more clinic approach and we can rely on what emerged from
trials and literature. Several authors suggest that the single
dosage of mepolizumab could be a limit in overweight-obese
patients, and the possibility to a weight-adjustment could be
useful. About that Mukherjee and coauthors have described a
trial where ten patients, demonstrating a non-fully response
to mepolizumab after 1 year of administration, after a 1-year
period of wash-out, have been treated with 3.0 mh/Kg of
reslizumab with an increase of QoL and decrease of sputum
and blood eosinophilia after 4 months of administration [51].
This could be used as a discriminant to choose one drug
rather than another. On the other hand mepolizumab seems
to have the same efficacy in the patients treated in the trials
both at the marketed dosage (100 mg) and at higher doses,
confirming its effectiveness regardless of weight, making it
safe and effective to be prescribed independently of the body
mass index (BMI) value [7, 10]. Regarding the anti-receptor
drug, benralizumab, an advantage could be the periodicity
of administration; indeed, after a “run-in” period where for
three months the dosage is at 4-week frequency, the drug
will be injected every 8 weeks. This therapeutic scheme could
be advantageous due to the fact that the intake of the drug
with a 8-week frequency would decrease the indirect costs
(lost work days, visits made, etc.), and, depending on the
cost of the drug agreed upon with the local health ministries,
also the direct ones. We could have greater clarity on the
choice of drugs with the development of single biomarkers
or panels of laboratory and clinical parameters, and real life
studies.
BioMed Research International 7
10. Conclusions
The wide variety of anti-IL-5 antagonists or IL-5 receptor
blockers allow to have alternative treatment options for
patients with severe hypereosinophilic patients. All the three
drugs herein reviewed displayed a good safety profile, and a
favorable clinical efficacy in the selected patients. It remains
true that we do not still have reliable predictive markers
to detect which single patient will respond individually to
each of such expensive treatments. Also, the different routes
of administrations would provide clinicians with the oppor-
tunity to choose the drug according to drug characteristic
and patient’s needs. At present, the best biomarker in patient
eligible for anti-IL-5 or IL-5ra is blood eosinophils, exhaled
nitric oxide, and clinical phenotyping (age of onset of asthma,
atopy, and presence of nasal polyposis). Predictive biomark-
ers allowing a better prescription of a personalized medicine
are needed, although the introduction in clinical practice of
novel biologics targeted to severe asthma represents a step
forward.
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